Detalhe da pesquisa
1.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med
; 387(8): 704-714, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-36001711
2.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33259589
3.
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Blood
; 134(21): 1811-1820, 2019 11 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31558467
4.
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Mult Scler
; 27(3): 420-429, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32351164
5.
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Lancet Oncol
; 19(4): 486-496, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29475723
6.
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Br J Haematol
; 176(3): 412-420, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27982425
7.
Taste coding of complex naturalistic taste stimuli and traditional taste stimuli in the parabrachial pons of the awake, freely licking rat.
J Neurophysiol
; 116(1): 171-82, 2016 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27121585
8.
Taste coding in the parabrachial nucleus of the pons in awake, freely licking rats and comparison with the nucleus of the solitary tract.
J Neurophysiol
; 111(8): 1655-70, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24381029
9.
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Blood Adv
; 8(2): 378-387, 2024 01 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37871300
10.
Dynamic transcription factor activity profiling in 2D and 3D cell cultures.
Biotechnol Bioeng
; 110(2): 563-72, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-22949103
11.
Cellular arrays for large-scale analysis of transcription factor activity.
Biotechnol Bioeng
; 108(2): 395-403, 2011 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-20812256
12.
Invasive Treatments for Low Back Disorders.
J Occup Environ Med
; 63(4): e215-e241, 2021 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33769405
13.
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Lancet Haematol
; 8(4): e254-e266, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33631112
14.
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
J Clin Oncol
; 39(15): 1609-1618, 2021 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33683917
15.
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Blood Adv
; 5(23): 5332-5343, 2021 12 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34547767
16.
Non-Invasive and Minimally Invasive Management of Low Back Disorders.
J Occup Environ Med
; 62(3): e111-e138, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31977923
17.
Taste Responses in the Nucleus of the Solitary Tract of Awake Obese Rats Are Blunted Compared With Those in Lean Rats.
Front Integr Neurosci
; 13: 35, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31417373
18.
Diagnostic Tests for Low Back Disorders.
J Occup Environ Med
; 61(4): e155-e168, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30694882
19.
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Lancet Haematol
; 6(2): e100-e109, 2019 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-30709431
20.
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Leuk Lymphoma
; 64(9): 1579-1582, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37341984